Nanoparticle engineering for vaccine delivery, presenting translational research on design principles and immunological targeting; expect detailed experimental and analytical insights.
Key Takeaways
- Major barrier in mucosal vaccine development is achieving localized immunity without systemic toxicity
- Here we engineered NanoCF501, a nanoparticulate STING agonist formulated with a 2-ethyl-2-oxazoline polymer
- NanoCF501 facilitates efficient mucus penetration and localized respiratory retention